These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9616276)

  • 21. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Klastersky J; Giner V; Bureau G; Thiriaux J; Dabouis G; Efremidis A; Ries F; Berchier MC; Sergysels R
    J Clin Oncol; 1994 Feb; 12(2):353-9. PubMed ID: 8113843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
    D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
    J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K; Laskin J; Ho C
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
    Pignon T; Ruggieri S; Boutin C; Gouvernet J; Irisson M; Juin P; Astoul P
    Cancer; 1999 May; 85(10):2144-50. PubMed ID: 10326692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Smit E; Moro-Sibilot D; Carpeño Jde C; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
    Lung Cancer; 2016 Feb; 92():35-40. PubMed ID: 26775594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Koumakis G; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
    Eur J Cancer; 1999 Sep; 35(9):1314-9. PubMed ID: 10658520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
    Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
    J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
    Couillard-Montminy V; Gagnon PY; Fortin S; Côté J
    J Oncol Pharm Pract; 2019 Jan; 25(1):44-51. PubMed ID: 28825377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer.
    Komuro M; Kaneko M; Narukawa M
    Tumori; 2015; 101(4):424-32. PubMed ID: 25908047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.